10.1038/s41593-020-0684-9 48 MellaR.SchmidtC
Chartoumpekis DV, Habeos EE, Psilopanagioti A (2024) Evaluating the effectiveness and underlying mechanisms of incretin-based treatments for hypothalamic obesity: A narrative review

however, it was associated with the highest rate of gastrointestinal adverse events ( A systematic review and meta-analysis conducted to investigate the efficacy of tirzepatide on glycated hemoglobin, fasting serum glucose, and body weight in patients with uncontrolled T2DM reported that tirzepatide significantly improved glycemic control and body weight with an acceptable safety profile ( The FDA has approved liraglutide (a maintenance dose of 3 mg injected daily), subcutaneous semaglutide (2.4 mg injected once weekly), and tirzepatide (515 mg injected once weekly) for chronic weight management in adults with body mass index (BMI) of 30 kg/m 2 or greater, or with a BMI of 27 kg/m 2 or greater with at least one weight-related condition (such as high BP, T2DM, or high cholesterol) to be used in addition to a reduced calorie diet and increased physical activity ( Overall, robust findings have showed that GLP-1 RAs effectively promote weight loss

16 announcing her "Ozempic pregnancy" with her boyfriend
Even though we knew for a long time that dysregulated insulin production was one of the causes of diabetes, especially, obviously Type 1 and Type 2 diabetes, we didn't know exactly why there was this dysregulation, so the GLP discovery helped us understand more about how insulin is created in the body